Brainstorm Cell Ther Boeing Bond
| GHDN Stock | EUR 2.69 0.00 0.00% |
Brainstorm Cell Ther has over 3.04 Million in debt which may indicate that it relies heavily on debt financing. . Brainstorm Cell's financial risk is the risk to Brainstorm Cell stockholders that is caused by an increase in debt.
Asset vs Debt
Equity vs Debt
Brainstorm Cell's liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. Brainstorm Cell's cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps Brainstorm Stock's retail investors understand whether an upcoming fall or rise in the market will negatively affect Brainstorm Cell's stakeholders.
For most companies, including Brainstorm Cell, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for Brainstorm Cell Therapeutics, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, Brainstorm Cell's management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
Brainstorm |
Given the importance of Brainstorm Cell's capital structure, the first step in the capital decision process is for the management of Brainstorm Cell to decide how much external capital it will need to raise to operate in a sustainable way. Once the amount of financing is determined, management needs to examine the financial markets to determine the terms in which the company can boost capital. This move is crucial to the process because the market environment may reduce the ability of Brainstorm Cell Therapeutics to issue bonds at a reasonable cost.
| Popular Name | Brainstorm Cell Boeing Co 2196 |
| Equity ISIN Code | US10501E2019 |
| Bond Issue ISIN Code | US097023DG73 |
| S&P Rating | Others |
| Maturity Date | 4th of February 2026 |
| Issuance Date | 4th of February 2021 |
| Coupon | 2.196 % |
Brainstorm Cell Ther Outstanding Bond Obligations
| Dana 575 percent | US235822AB96 | Details | |
| Boeing Co 2196 | US097023DG73 | Details | |
| BNP Paribas FRN | USF1R15XK367 | Details | |
| AerCap Global Aviation | US00773HAA59 | Details |
Understaning Brainstorm Cell Use of Financial Leverage
Brainstorm Cell's financial leverage ratio helps determine the effect of debt on the overall profitability of the company. It measures Brainstorm Cell's total debt position, including all outstanding debt obligations, and compares it with Brainstorm Cell's equity. Financial leverage can amplify the potential profits to Brainstorm Cell's owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if Brainstorm Cell is unable to cover its debt costs.
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of central nervous system adult stem cell therapies designed to address the unmet medical needs of patients with debilitating neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was founded in 2000 and is headquartered in New York, New York. BRAINSTORM operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 31 people. Please read more on our technical analysis page.
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Brainstorm Stock
When determining whether Brainstorm Cell Ther offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Brainstorm Cell's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Brainstorm Cell Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Brainstorm Cell Therapeutics Stock:Check out the analysis of Brainstorm Cell Fundamentals Over Time. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
What is Financial Leverage?
Financial leverage is the use of borrowed money (debt) to finance the purchase of assets with the expectation that the income or capital gain from the new asset will exceed the cost of borrowing. In most cases, the debt provider will limit how much risk it is ready to take and indicate a limit on the extent of the leverage it will allow. In the case of asset-backed lending, the financial provider uses the assets as collateral until the borrower repays the loan. In the case of a cash flow loan, the general creditworthiness of the company is used to back the loan. The concept of leverage is common in the business world. It is mostly used to boost the returns on equity capital of a company, especially when the business is unable to increase its operating efficiency and returns on total investment. Because earnings on borrowing are higher than the interest payable on debt, the company's total earnings will increase, ultimately boosting stockholders' profits.Leverage and Capital Costs
The debt to equity ratio plays a role in the working average cost of capital (WACC). The overall interest on debt represents the break-even point that must be obtained to profitability in a given venture. Thus, WACC is essentially the average interest an organization owes on the capital it has borrowed for leverage. Let's say equity represents 60% of borrowed capital, and debt is 40%. This results in a financial leverage calculation of 40/60, or 0.6667. The organization owes 10% on all equity and 5% on all debt. That means that the weighted average cost of capital is (.4)(5) + (.6)(10) - or 8%. For every $10,000 borrowed, this organization will owe $800 in interest. Profit must be higher than 8% on the project to offset the cost of interest and justify this leverage.Benefits of Financial Leverage
Leverage provides the following benefits for companies:- Leverage is an essential tool a company's management can use to make the best financing and investment decisions.
- It provides a variety of financing sources by which the firm can achieve its target earnings.
- Leverage is also an essential technique in investing as it helps companies set a threshold for the expansion of business operations. For example, it can be used to recommend restrictions on business expansion once the projected return on additional investment is lower than the cost of debt.